Effects of α-Blockers, Antimuscarinics, or Combination Therapy in Relieving Ureteral Stent-Related Symptoms: A Meta-Analysis

Journal of Endourology

Volumn 29, Issue 6, 2015, Pages 650-656

  Zhou, Liang ^a   Cai, Xiang ^a   Li, Hong ^a   Wang, Kun Jie ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALFUZOSIN; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; MUSCARINIC RECEPTOR BLOCKING AGENT; SOLIFENACIN; TAMSULOSIN; TOLTERODINE;

ARTICLE; CONSERVATIVE TREATMENT; DOUBLE J STENT; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; HUMAN; INTERNATIONAL PROSTATE SYMPTOM SCORE; META ANALYSIS; MONOTHERAPY; ORTHOSTATIC HYPOTENSION; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); STENT COMPLICATION; SYSTEMATIC REVIEW; URETER DISEASE; URETERAL STENT SYMPTOM QUESTIONNAIRE; URINARY TRACT DISEASE ASSESSMENT; VISUAL ANALOG SCALE; XEROSTOMIA; ADVERSE EFFECTS; COMBINATION DRUG THERAPY; MALE; PAIN MEASUREMENT; PAIN, POSTOPERATIVE; STENT; URETERAL OBSTRUCTION;

ADRENERGIC ALPHA-ANTAGONISTS; DRUG THERAPY, COMBINATION; HUMANS; MALE; MUSCARINIC ANTAGONISTS; PAIN MEASUREMENT; PAIN, POSTOPERATIVE; STENTS; URETERAL OBSTRUCTION;

EID: 84931043086     PISSN: 08927790     EISSN: 1557900X     Source Type: Journal    
DOI: 10.1089/end.2014.0715     Document Type: Article

References (32)

1. Zimskind PD, Fetter TR, Wilkerson JL. Clinical use of long-term indwelling silicone rubber ureteral splints inserted cystoscopically. J Urol 1967;97:840-844.
2. Haleblian G, Kijvikai K, de la Rosette J, Preminger G. Ureteral stenting and urinary stone management: A systematic review. J Urol 2008;179:424-430.
3. Joshi HB, Okeke A, Newns N, et al. Characterization of urinary symptoms in patients with ureteral stents. Urology 2002;59:511-516.
4. Thomas R. Indwelling ureteral stents: Impact of material and shape on patient comfort. J Endourol 1993;7:137-140.
5. Joshi HB, Stainthorpe A, MacDonagh RP, et al. Indwelling ureteral stents: Evaluation of symptoms, quality of life and utility. J Urol 2003;169:1065-1069.
6. Joshi HB, Newns N, Stainthorpe A, et al. Ureteral stent symptom questionnaire: Development and validation of a multidimensional quality of life measure. J Urol 2003;169:1060-1064.
7. Dellis A, Joshi HB, Timoney AG, Keeley FX Jr. Relief of stent related symptoms: Review of engineering and pharmacological solutions. J Urol 2010;184:1267-1272.
8. Lamb AD, Vowler SL, Johnston R, et al. Meta-analysis showing the beneficial effect of alpha-blockers on ureteric stent discomfort. BJU Int 2011;108:1894-1902.
9. Yakoubi R, Lemdani M, Monga M, et al. Is there a role for alpha-blockers in ureteral stent related symptoms? A systematic review and meta-analysis. J Urol 2011;186:928-934.
10. Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: Is blinding necessary? Control Clin trials 1996;17:1-12.
11. Damiano R, Autorino R, De Sio M, et al. Effect of tamsulosin in preventing ureteral stent-related morbidity: A prospective study. J Endourol 2008;22:651-656.
12. Beddingfield R, Pedro RN, Hinck B, et al. Alfuzosin to relieve ureteral stent discomfort: A prospective, randomized, placebo controlled study. J Urol 2009;181:170-176.
13. Lee SJ, Yoo C, Oh CY, et al. Stent position is more important than alpha-blockers or anticholinergics for stentrelated lower urinary tract symptoms after ureteroscopic ureterolithotomy: A prospective randomized study. Korean J Urol 2010;51:636-641.
14. Mo K, Lee KS, Seo YJ, et al. Effects of alpha-blocker on lower urinary tract symptoms due to ureteral stent: Prospective study. J Urol 2007;177:419-419.
15. Nazim SM, Ather MH. Alpha-blockers impact stent-related symptoms: A randomized, double-blind, placebo-controlled trial. J Endourol 2012;26:1237-1241.
16. Wang CJ, Huang SW, Chang CH. Effects of specific alpha-1A/1D blocker on lower urinary tract symptoms due to double-J stent: A prospectively randomized study. Urol Res 2009;37:147-152.
17. Wang CJ, Huang SW, Chang CH. Effects of tamsulosin on lower urinary tract symptoms due to double-j stent: A prospective study. Urol Int 2009;83:66-69.
18. Deliveliotis C, Chrisofos M, Gougousis E, et al. Is there a role for alpha1-blockers in treating double-J stent-related symptoms? Urology 2006;67:35-39.
19. Tehranchi A, Rezaei Y, Khalkhali H, Rezaei M. Effects of terazosin and tolterodine on ureteral stent related symptoms: A double-blind placebo-controlled randomized clinical trial. Int Braz J Urol 2013;39:832-840.
20. Dellis AE, Keeley FX Jr, Manolas V, Skolarikos AA. Role of alpha-blockers in the treatment of stent-related symptoms: A prospective randomized control study. Urology 2014;83:56-61.
21. Navanimitkul N, Lojanapiwat B. Efficacy of tamsulosin 0.4 mg/day in relieving double-j stent-related symptoms: A randomized controlled study. J Int Med Res 2010;38:1436-1441.
22. Park SC, Jung SW, Lee JW, Rim JS. The effects of tolterodine extended release and alfuzosin for the treatment of double-j stent-related symptoms. J Endourol 2009;23:1913-1917.
23. Shalaby E, Ahmed AF, Maarouf A, et al. Randomized controlled trial to compare the safety and efficacy of tamsulosin, solifenacin, and combination of both in treatment of double-j stent-related lower urinary symptoms. Adv Urol 2013;2013:752382.
24. Davenport K, Timoney AG, Keeley FX. A comparative in vitro study to determine the beneficial effect of calcium-channel and alpha(1)-adrenoceptor antagonism on human ureteric activity. BJU Int 2006;98:651-655.
25. Davenport K, Timoney AG, Keeley FX Jr. Effect of smooth muscle relaxant drugs on proximal human ureteric activity in vivo: A pilot study. Urol Res 2007;35: 207-213.
26. Irani J, Siquier J, Pires C, et al. Symptom characteristics and the development of tolerance with time in patients with indwelling double-pigtail ureteric stents. BJU Int 1999;84:276-279.
27. Andersson KE. Antimuscarinics for treatment of overactive bladder. Lancet Neurol 2004;3:46-53.
28. Yamaguchi O. Latest treatment for lower urinary tract dysfunction: Therapeutic agents and mechanism of action. Int J Urol 2013;20:28-39.
29. Norris RD, Sur RL, Springhart WP, et al. A prospective, randomized, double-blinded placebo-controlled comparison of extended release oxybutynin versus phenazopyridine for the management of postoperative ureteral stent discomfort. Urology 2008;71:792-795.
30. Mosli HA, Farsi HM, al-Zimaity MF, et al. Vesicoureteral reflux in patients with double pigtail stents. J Urol 1991;146:966-969.
31. Hao N, Tian Y, Liu W, et al. Antimuscarinics and alpha-blockers or alpha-blockers monotherapy on lower urinary tract symptoms - A meta-analysis. Urology 2014;83:556-562.
32. Lim KT, Kim YT, Lee TY, Park SY. Effects of tamsulosin, solifenacin, and combination therapy for the treatment of ureteral stent related discomforts. Korean J Urol 2011;52:485-488.